Forte Biosciences (FBRX) Current Deferred Revenue (2016 - 2019)
Forte Biosciences' (FBRX) quarterly Current Deferred Revenue came in at $9000.0 in Q3 2019, down 75.0% year-on-year from $36000.0 in Q3 2018, and down 50.0% on a QoQ basis from $18000.0 in Q2 2019.
Forte Biosciences (FBRX) Current Deferred Revenue (2016 - 2019) Analysis & Trends
Forte Biosciences (FBRX) has 4 years of Current Deferred Revenue data on file, last reported at $9000.0 in Q3 2019.
- On a quarterly basis, Current Deferred Revenue fell 75.0% year-over-year to $9000.0 in Q3 2019; TTM through Sep 2019 was $9000.0, a 75.0% decrease from a year earlier, with the FY2018 full-year figure at $36000.0, changed 0.0% from the prior year.
- Current Deferred Revenue for Q3 2019 stood at $9000.0, down from $18000.0 in the prior quarter.
- Over the last five years, Current Deferred Revenue for FBRX reached as high as $1.0 million in Q2 2018 and fell as low as $9000.0 in Q3 2019.
- Historically, Current Deferred Revenue has averaged $116833.3 across 4 years, with a median of $36000.0 in 2017.
- Across the five-year window, Current Deferred Revenue jumped 2426.83% in 2018 and slumped 98.26% in 2019, its largest moves.
- Year by year, Current Deferred Revenue stood at $45000.0 in 2016, then declined by 20.0% to $36000.0 in 2017, then changed by 0.0% to $36000.0 in 2018, then slumped by 75.0% to $9000.0 in 2019.
- Per Business Quant data, the three most recent Current Deferred Revenue figures were $9000.0 in Q3 2019, $18000.0 in Q2 2019, and $27000.0 in Q1 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Forte Biosciences | 174.08 Mn | 115.88 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2019 | 9,000.00 |
| Jun 30, 2019 | 18,000.00 |
| Mar 31, 2019 | 27,000.00 |
| Dec 31, 2018 | 36,000.00 |
| Sep 30, 2018 | 36,000.00 |
| Jun 30, 2018 | 1.04 Mn |
| Mar 31, 2018 | 36,000.00 |
| Dec 31, 2017 | 36,000.00 |
| Sep 30, 2017 | 41,000.00 |
| Jun 30, 2017 | 41,000.00 |
| Mar 31, 2017 | 41,000.00 |
| Dec 31, 2016 | 45,000.00 |